GUCY2C and adenocarcinoma: One of the most well characterized aberrations in cGMP signaling involves decreased expression of the peptide hormones, guanylin and uroguanylin, in colorectal adenomas and adenocarcinomas that is accompanied by an increased expression of the guanylin receptor, guanylyl cyclase C (GC-C) [78,79,80,81].